Monopar Therapeutics (NASDAQ:MNPR) Earns “Buy” Rating from Chardan Capital

Monopar Therapeutics (NASDAQ:MNPR)‘s stock had its “buy” rating reaffirmed by stock analysts at Chardan Capital in a report issued on Thursday,Benzinga reports. They presently have a $100.00 price objective on the stock. Chardan Capital’s target price would indicate a potential upside of 65.62% from the company’s previous close.

MNPR has been the subject of several other reports. Raymond James Financial cut Monopar Therapeutics from a “strong-buy” rating to an “outperform” rating and reduced their target price for the stock from $142.00 to $123.00 in a research report on Friday, November 14th. Leerink Partners started coverage on Monopar Therapeutics in a research report on Monday, November 10th. They set an “outperform” rating and a $115.00 price target for the company. Jones Trading upgraded shares of Monopar Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Friday, October 10th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Monopar Therapeutics in a research note on Wednesday, January 21st. Finally, Oppenheimer set a $115.00 target price on shares of Monopar Therapeutics and gave the company an “outperform” rating in a research report on Thursday, October 2nd. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $107.00.

Monopar Therapeutics Trading Down 10.3%

Monopar Therapeutics stock opened at $60.38 on Thursday. Monopar Therapeutics has a 1-year low of $26.06 and a 1-year high of $105.00. The firm has a market capitalization of $403.52 million, a PE ratio of -17.55 and a beta of 1.46. The firm’s 50 day simple moving average is $71.94 and its 200 day simple moving average is $65.44.

Monopar Therapeutics (NASDAQ:MNPR) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.02). Research analysts forecast that Monopar Therapeutics will post -1.65 earnings per share for the current year.

Insider Transactions at Monopar Therapeutics

In other news, CFO Quan Anh Vu bought 1,500 shares of the business’s stock in a transaction on Friday, December 26th. The stock was acquired at an average price of $69.95 per share, with a total value of $104,925.00. Following the completion of the purchase, the chief financial officer directly owned 1,500 shares in the company, valued at $104,925. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 20.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Monopar Therapeutics

A number of institutional investors have recently made changes to their positions in MNPR. Goldman Sachs Group Inc. bought a new position in shares of Monopar Therapeutics during the 1st quarter valued at $673,000. Jane Street Group LLC bought a new position in shares of Monopar Therapeutics during the first quarter valued at about $377,000. AlphaQuest LLC grew its stake in shares of Monopar Therapeutics by 46.8% during the second quarter. AlphaQuest LLC now owns 1,784 shares of the company’s stock valued at $64,000 after buying an additional 569 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Monopar Therapeutics by 99.7% in the second quarter. Geode Capital Management LLC now owns 96,919 shares of the company’s stock worth $3,468,000 after buying an additional 48,379 shares during the period. Finally, Police & Firemen s Retirement System of New Jersey bought a new stake in shares of Monopar Therapeutics in the 2nd quarter valued at about $34,000. Hedge funds and other institutional investors own 1.83% of the company’s stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.